» Articles » PMID: 24523022

Biochemical/metabolic Changes Associated with Hepatocellular Carcinoma Development in Mice

Overview
Journal Tumour Biol
Publisher Sage Publications
Specialty Oncology
Date 2014 Feb 14
PMID 24523022
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality after lung and stomach cancers. This work was undertaken to investigate some of the biochemical mediators/pathways associated with or implicated in the pathogenesis of HCC. Male albino mice were classified into two groups: normal control group and HCC group. Early stage HCC was induced by injection of diethylnitrosamine (DEN) i.p. 200 mg/kg as a single dose, and after 2 weeks, the mice were given i.p. injection of thioacetamide (TAA) 100 mg/kg twice per week for 4 weeks. Mice were left for further 2 weeks without any treatment, after which, mice were sacrificed; blood and liver samples were collected. Serum was used for determination of activities of glucose-6-phosphate dehydrogenase (G6PDH) and aldolase as well as levels of insulin-like growth factor-1 (IGF-1) and epithelial cadherin (E-cadherin). One portion of the liver was used for histopathological examination and immunohistochemical staining of the tumor suppressor p53 protein. Another portion of the liver was used for determination of citrate synthase activity. Induction of HCC in mice resulted in significant increase in G6PDH and aldolase activities, and E-cadherin level, but significant decrease in IGF-1. HCC mice group showed moderate expression of p53 protein. These results suggest that the molecular pathogenesis of HCC in mice involves reduction of serum level of IGF-1 and increased serum level of E-cadherin accompanied by dysregulation of p53 protein expression. HCC was also associated with reprogrammed metabolic profile shifted toward increased glycolysis and lipogenesis.

Citing Articles

Metabolic reprogramming of glucose: the metabolic basis for the occurrence and development of hepatocellular carcinoma.

Wang K, Li X, Guo S, Chen J, Lv Y, Guo Z Front Oncol. 2025; 15:1545086.

PMID: 39980550 PMC: 11839411. DOI: 10.3389/fonc.2025.1545086.


Unraveling the Sweet Secrets of HCC: Glucometabolic Rewiring in Hepatocellular Carcinoma.

Bhat S, Farooq Z, Ismail H, Corona-Avila I, Khan M Technol Cancer Res Treat. 2023; 22:15330338231219434.

PMID: 38083797 PMC: 10718058. DOI: 10.1177/15330338231219434.


The Role of Mass Spectrometry in Hepatocellular Carcinoma Biomarker Discovery.

Shen E, U M, Cox I, Taylor-Robinson S Metabolites. 2023; 13(10).

PMID: 37887384 PMC: 10609223. DOI: 10.3390/metabo13101059.


Molecular Targets and Signaling Pathways of microRNA-122 in Hepatocellular Carcinoma.

Chun K Pharmaceutics. 2022; 14(7).

PMID: 35890276 PMC: 9316959. DOI: 10.3390/pharmaceutics14071380.


Therapeutic efficacy of a extract in a rat model of hepatocellular carcinoma: Histopathological aspects.

Kerdput V, Nilbu-Nga C, Kaewnoonual N, Itharat A, Pongsawat S, Pradidarcheep W J Tradit Complement Med. 2021; 11(5):400-408.

PMID: 34522634 PMC: 8427478. DOI: 10.1016/j.jtcme.2021.02.001.


References
1.
Takeuchi H, Nakamoto T, Mori Y, Kawakami M, Mabuchi H, Ohishi Y . Comparative effects of dietary fat types on hepatic enzyme activities related to the synthesis and oxidation of fatty acid and to lipogenesis in rats. Biosci Biotechnol Biochem. 2001; 65(8):1748-54. DOI: 10.1271/bbb.65.1748. View

2.
Mucci L, Stark J, Pollak M, Li H, Kurth T, Stampfer M . Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev. 2010; 19(2):484-91. PMC: 2820127. DOI: 10.1158/1055-9965.EPI-09-0836. View

3.
Soyama A, Eguchi S, Takatsuki M, Kawashita Y, Hidaka M, Tokai H . Significance of the serum level of soluble E-cadherin in patients with HCC. Hepatogastroenterology. 2008; 55(85):1390-3. View

4.
Novosyadlyy R, Dargel R, Scharf J . Expression of insulin-like growth factor-I and insulin-like growth factor binding proteins during thioacetamide-induced liver cirrhosis in rats. Growth Horm IGF Res. 2005; 15(5):313-23. DOI: 10.1016/j.ghir.2005.06.015. View

5.
Pinto P, Kaplan A, Van Dreal P . Aldolase. II. Spectrophotometric determination using an ultraviolet procedure. Clin Chem. 1969; 15(5):349-60. View